AR095559A1 - Monoterapia con oligonucleótidos anti-clusterina para tratar el cáncer - Google Patents

Monoterapia con oligonucleótidos anti-clusterina para tratar el cáncer

Info

Publication number
AR095559A1
AR095559A1 ARP140101181A ARP140101181A AR095559A1 AR 095559 A1 AR095559 A1 AR 095559A1 AR P140101181 A ARP140101181 A AR P140101181A AR P140101181 A ARP140101181 A AR P140101181A AR 095559 A1 AR095559 A1 AR 095559A1
Authority
AR
Argentina
Prior art keywords
clusterine
oligonucleotides
monotherapy
treat cancer
cancer
Prior art date
Application number
ARP140101181A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR095559A1 publication Critical patent/AR095559A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método para tratar un cáncer en un sujeto, que está basado en la administración de un oligonucleótido anti-clusterina como monoterapia. Composiciones útiles para tratar el cáncer que comprenden oligonucleótidos anti-clusterina que tienen la secuencia CAGCAGCAGAGTCTTCATCAT (SEQ ID Nº 1). Composiciones farmacéuticas útiles para tratar el cáncer que comprenden oligonucleótidos anti-clusterina que tienen la secuencia CAGCAGCAGAGTCTTCATCAT (SEQ ID Nº 1) y cuyo esqueleto de fosforotioato comprende unidades de azúcar que presentan modificaciones de 2-O-metoxietilo en los nucleótidos 1 a 4 y 18 a 21, comprende desoxinucleótidos 2 en las posiciones 5 a 17 y comprende 5-metilcitosinas en las posiciones 1, 4 y 19.
ARP140101181A 2013-03-14 2014-03-17 Monoterapia con oligonucleótidos anti-clusterina para tratar el cáncer AR095559A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361782584P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095559A1 true AR095559A1 (es) 2015-10-28

Family

ID=51530000

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101181A AR095559A1 (es) 2013-03-14 2014-03-17 Monoterapia con oligonucleótidos anti-clusterina para tratar el cáncer

Country Status (5)

Country Link
US (1) US20140275215A1 (es)
AR (1) AR095559A1 (es)
CA (1) CA2900533A1 (es)
TW (1) TW201513871A (es)
WO (1) WO2014159775A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101052289B1 (ko) * 2002-08-21 2011-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 클러스테린 양의 감소에 의한 흑색종의 치료
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
DK2504363T3 (da) * 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
PE20140647A1 (es) * 2011-05-19 2014-06-05 Teva Pharma Metodo para tratamiento de cancer de pulmon de celulas no pequenas

Also Published As

Publication number Publication date
WO2014159775A1 (en) 2014-10-02
TW201513871A (zh) 2015-04-16
CA2900533A1 (en) 2014-10-02
US20140275215A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
UY37464A (es) Métodos para tratar infecciones por el virus filoviridae
CO2019003846A2 (es) Tratamiento aav de la enfermedad de huntington
CL2018000899A1 (es) Compuestos y métodos para modular expresión de angiotensinógeno.
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
AR091090A1 (es) Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas
AR090869A1 (es) COMPOSICIONES DE ARNi DE SERPINC1 Y SUS METODOS DE USO
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
EA201491953A1 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ МИКРОРНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-21
NZ631537A (en) Compositions and methods for modulating apolipoprotein c-iii expression
NZ630596A (en) Methods for treatment of alport syndrome
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
AR099303A1 (es) Construcciones de aptámeros
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
EA201791471A1 (ru) Способы применения антисмысловых олигонуклеотидов smad7
EA201791986A1 (ru) Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза
BR112017002629A2 (pt) decoys de oligonucleotídeo para o tratamento de dor
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
MX2015012063A (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
AR083445A1 (es) siARN CONTRA LA FIBROSIS
AR094492A1 (es) Métodos y composiciones para el control de pestes vegetales
BR112018010736A2 (pt) oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos
AR095559A1 (es) Monoterapia con oligonucleótidos anti-clusterina para tratar el cáncer
CL2013003466A1 (es) Construcción de arn que comprende una secuencia de segmento sentido y una antisentido del gen p0 del genoma del virus del amarilleo moderado de la remolacha (bmyv), metodo para inducir tolerancia al virus bmyv.
UA117563C2 (uk) Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл

Legal Events

Date Code Title Description
FB Suspension of granting procedure